Cargando…

MON-312 The Effects of Cabergoline in Pre-Surgical and Recurrence Periods of Cushing’s Disease Patients

BACKGROUND: Dopaminergic agonist cabergoline (CAB) has been used in pharmacological treatment of Cushing’s disease (CD). The effect is attributed to the frequent expression of subtype 2 dopamine receptor in corticotropic tumors. However, in vivo studies demonstrated normalization of urinary cortisol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pereira, Ana Julia Garcia, Andrade, Natália Xavier S, Musolino, Nina Rosa de Castro, Cescato, Valter Angelo Sperling, da Silva, Gilberto Ochman, Fragoso, Maria Candida Barisson Villares, Bronstein, Marcello Delano, Machado, Marcio Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209226/ http://dx.doi.org/10.1210/jendso/bvaa046.572

Ejemplares similares

MON-404 Reversible Dilated Cardiomyopathy in a Severe Case of Cushing’s Disease
por: Valente do Couto, Hugo, et al.
Publicado: (2019)

MON-407 Tumor Control after Radiotherapy and Temozolomide in a Cushing's Disease Patient with Giant Aggressive Pituitary Tumor
por: Valente do Couto, Hugo, et al.
Publicado: (2019)

MON-250 Late Diagnosis of ACTH-secreting Pulmonary Neuroendocrine Tumor by Repeated (68)Ga Dotatate Pet/ct: Influence of Tumor Size in Abnormal Uptake?
por: Andrade, Natália Xavier S, et al.
Publicado: (2020)

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
por: Machado, Márcio Carlos, et al.
Publicado: (2021)

MON-LB60 Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Prospective Study
por: Corrêa Portari, Luiz Henrique, et al.
Publicado: (2020)

SUN-445 A Brazilian Multicentric Study Evaluating Pregnancies Induced by Cabergoline in Patients Harboring Prolactinomas
por: Sant Anna, Beatriz, et al.
Publicado: (2019)

MON-328 Disorders of Glucose Metabolism in Cushing Syndrome in Uzbekistan
por: Narimova, Gulchekhra Djumaniyazovna, et al.
Publicado: (2020)

MON-LB080 Change of T2-Weighted Intensity of Prolactinoma as a Predictable Value for Relapse of Hyperprolactinemia after Cabergoline Withdrawal
por: Kim, Kyungwon, et al.
Publicado: (2019)

MON-412 Subclinical Cushing's Disease and the Importance of Broad Differential Diagnoses
por: Walker, Michelle, et al.
Publicado: (2019)

MON-461 Drug Repurposing to Explore Novel Treatment for Cushing Disease
por: Zhang, Dongyun, et al.
Publicado: (2019)

MON-403 Osteoporosis: A Frequently Neglected Consequence of Cushing's Disease
por: Pedro, Jorge, et al.
Publicado: (2019)

MON-405 Cushing's Disease: An Oligosymptomatic Patient with ACTH-Secreting Pituitary Macroadenoma
por: Manrique Franco, Katty, et al.
Publicado: (2019)

MON-321 AgRP and Food Cravings Decrease with Treatment of Cushing’s Disease
por: Haseltine, Katherine N, et al.
Publicado: (2020)

SAT-270 Priapism Secondary to Cabergoline
por: Amir, Maryam, et al.
Publicado: (2020)

MON-264 Pleotropic Clinical Presentation in Two Brazilians Patients with Confirmed IgG4-Related Hypophysitis
por: de Oliveira, Rafael, et al.
Publicado: (2020)

MON-318 Acute, Life-Threatening and Perioperative Complications in Cushing’s Syndrome: Predictors and Outcomes
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2020)

MON-295 Desmopressin Test in Silent Corticothoph Pituitary Adenomas, a Preliminary Study - a Comparison with Cushing Disease
por: Huayllas, Martha Katherine, et al.
Publicado: (2020)

MON-435 The Responsiveness To Ddavp Test Predicts Usp8 Mutation In Patients With Cushing's Disease
por: Shichi, Hiroki, et al.
Publicado: (2019)

MON-408 Development of Rapidly Progressive Cushing's Disease Following Pituitary Apoplexy Several Years Prior
por: Ortegon Zambrano, Pilar, et al.
Publicado: (2019)

MON-411 Psychological Disturbance And Weight Gain; Early Identification Of Cushing’S Disease In A Teenage Patient.
por: Hasan, Sana
Publicado: (2019)

MON-LB078 Desmopressin Stimulated Salivary Cortisol as a Suplementary Tool in the Diagnosis of Cushing's Syndrome
por: Firme, Ricardo
Publicado: (2019)

MON-457 One in Five Patients Develop Multiple Hormone Deficiencies Following Radiotherapy for Acromegaly or Cushing's Disease
por: Shen, Angeline, et al.
Publicado: (2019)

MON-LB58 The Use of 11C Methionine PET CT In Localization of ACTH Dependent Cushing’s Disease
por: ElEbrashy, Shady Ibrahim, et al.
Publicado: (2020)

Treatment of Postsurgical Clinically Nonfunctioning Pituitary Adenomas Remnants With Cabergoline
por: Vieira, Marina C M, et al.
Publicado: (2021)

MON-410 Ectopic ACTH- Secreting Tumor Causing Rapidly Progressive Cushing’s Syndrome Remains an Elusive Localization Diagnosis
por: Anaya Noubleau, Axa, et al.
Publicado: (2019)

SAT-LB47 Tension Pneumothorax Following Cabergoline Initiation for Macroprolactinoma
por: Go, Muriel Tania, et al.
Publicado: (2020)

SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma
por: Díaz-Balzac, Carlos A, et al.
Publicado: (2020)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

MON-444 Defining Remission In Cushing Syndrome After Tumor Resection In Cases Of Non-suppressed Postoperative Serum Cortisol Levels
por: McGlotten, Raven, et al.
Publicado: (2019)

MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
por: Castlen, Joseph, et al.
Publicado: (2019)

MON-LB51 Stimulation for Bilateral Inferior Petrosal Sinus Sampling May Be Unnecessary for Diagnosis of ACTH Dependent Cushing Syndrome
por: Builes-barrera, Carlos Alfonso, et al.
Publicado: (2020)

MON-329 Diagnostic Utility of Overnight High Dose Dexamethasone Suppression Test for Differentiating the Etiology of ACTH Dependent Cushing’s Syndrome
por: Yadav, Subhash B, et al.
Publicado: (2020)

MON-322 The Characteristic of Reproductive Disorders in Women with ACTH-Dependent Cushing Syndrome in the Republic of Uzbekistan (RUz) and Republic of Karakalpakstan (RKK)
por: Khalimova, Zamira Yusufovna, et al.
Publicado: (2020)

SAT-278 Vaginal Cabergoline: A Simple Solution to a Challenging Problem
por: Abuaisha, Munder, et al.
Publicado: (2020)

SAT-272 Pituitary Macroadenoma Co-Secreting TSH and PRL Responsive to Cabergoline
por: Tirumalasetty, Saritha, et al.
Publicado: (2020)

ODP299 Cabergoline Administration Markedly Improves Cognitive Impairment Associated with Macroprolactinoma
por: Hoang, Thanh, et al.
Publicado: (2022)

FRI322 Lack Of Tumor Size Change With Long-term Cabergoline For Prolactinoma
por: Bendaram, Snigdha Reddy, et al.
Publicado: (2023)

SUN-312 Strikingly Low Prevalence of Pituitary Incidentalomas in Our Hospital
por: Sosa, Natalia, et al.
Publicado: (2020)

ODP312 Giant Silent Corticotroph Adenoma: Presentation of 3 Cases
por: Oliveira, Miriam C, et al.
Publicado: (2022)

FRI312 Diplopia And Headache After Treatment With GnRH Agonist
por: Zakkar, Adam A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jncmb0focsqcap63d6k201i720